CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
15 août 2024 12h17 HE
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
15 août 2024 09h00 HE
|
Tevogen Bio Inc
Tevogen Bio Reports Second Quarter 2024 Financial Results
ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
15 août 2024 05h00 HE
|
ANEW MEDICAL, INC.
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for...
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14 août 2024 16h05 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
14 août 2024 16h05 HE
|
Fractyl Health, Inc.
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
14 août 2024 16h05 HE
|
Turnstone Biologics Corp.
Turnstone reports second quarter 2024 financial results and provides recent business highlights
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14 août 2024 16h01 HE
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13 août 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity
13 août 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to...
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
13 août 2024 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...